Exome Sequencing: is also known as whole exome sequencing (WES). It is a genomic technique for sequencing all of the protein-coding region of genes in a genome. It consists of two steps: the first step is to select only the subset of DNA that encodes proteins.
Acral lentiginous melanoma (ALM) is a rare sun-shielded melanoma subtype associated with worse survival than cutaneous melanoma (CM), a more common form of skin cancer linked to exposure to u...
DATE: September 19, 2017TIME: 10:30am PDT/ 1:30pm EDT/ 7:30pm CESTPart 1 – Cigall Kadoch, Ph.D. (30 min.)Exome- and genome-wide sequencing studies in human cancer have...
DATE: June 27, 2017TIME: 8:00am PT, 11:00am ETThe purpose of this study is to identify genetic variants that influence cellular responses, and patterns of M.tb infection and growth in h...
The Instrumentation Group at the BC Cancer Agency’s Genome Sciences Centre (GSC) is unusual in having an engineering group and extensive prototyping facilities embedded in a biomedical...
I’ll talk about Strand NGS Server, our server-client NGS offering. Strand NGS server is geared towards small-to-medium scale clinical labs with high-volume sequencing throughputs and lo...
Much has been said about the promise of Next Generation Sequencing (NGS) to revolutionise diagnosis of rare diseases, and there are many examples of success in this arena. However, the majori...
It was 10 years ago that Illumina first launched the Genome Analyzer II, the world’s first high-throughput sequencing platform. That system could produce one billion bps of sequen...
Many computational approaches exist for predicting the effects of amino acid substitutions from protein sequence. These are often (incorrectly) used for judging disease predisposition from in...
DATE: April 18, 2017TIME: 7:30am PT, 10:30am ETLabs large and small that conduct genomic studies are looking for ways to vastly improve NGS sample prep, especially from challenging FFPE...
DATE: February 7, 2017TIME: 10:00am PT, 1:00pm ETIn this webinar, Jeffrey G. Reid, PhD, Executive Director and Head of Genome Informatics at Regeneron Pharmaceuticals, will sh...
DATE: November 16, 2016
TIME: 8:00am PT, 11:00am ET
Breast cancer is the most commonly diagnosed cancer in women and is the second leading cause of cancer death among wo...
Whole genome and exome sequencing is being widely used to identify disease-causing variants in patients with hereditary and rare diseases. Discovering the true disease-causing variants often...
Tumor heterogeneity has been known for a while but quantifying heterogeneity is still a challenge. NGS is the method of choice in the analysis of tumor heterogeneity, however, there are...
Millions of individuals have been sequenced or genotyped and linked with medical records, providing an exciting opportunity for therapeutic target discovery. My lab has been using a resilienc...
Targeted sequencing assays are increasingly used to identify tumor mutations that guide therapeutic decisions. Interpretation of a cancer variant’s origin and therapeutic impact poses a...
It is estimated that by the end of this year more than 1 million people worldwide will have had their genome sequenced. Genomic sequencing is increasingly being integrated into clinical care,...
The rapid implementation of next generation sequencing is changing how genetics and genomics are applied in a clinical setting. However, the quickly evolving technology can be challenging to...
Human breast tumors have been shown to exhibit extensive inter- and intra-tumor heterogeneity. While recent advances in genomic technologies have allowed us to deconvolute this heterogeneity,...
DNASTAR offers an integrated suite of software for accurate assembly and analysis of sequence data from all major next-generation sequencing platforms supporting key workflows including de no...
It has been estimated that every human being carries ~20 rare “natural human gene knockouts”-DNA variants in protein-coding regions of the genome that partially or completely inac...
Oncologists and pathologists are increasingly utilizing information on genomic alterations in tumors to help guide patient care and treatment. Personalis, Inc., a genomic sequencing and inter...
Cancer remains the second leading cause of death in the United States. Most tumors arise from a myriad of genetic changes that dysregulate cell growth and prompt survival. Ident...
Recent advances in next-generation sequencing (NGS) have helped to accelerate the pace of discovery in the field of genetic disease research and testing. The ability to analyze multiple genes...
Medical genetics is a specialty of medicine that encompasses patients at all ages (prenatal, pediatric, adult), as well as all organ systems. As the genetic causes of more diseases have been ...
Acral lentiginous melanoma (ALM) is a rare sun-shielded melanoma subtype associated with worse survival than cutaneous melanoma (CM), a more common form of skin cancer linked to exposure to u...
DATE: September 19, 2017TIME: 10:30am PDT/ 1:30pm EDT/ 7:30pm CESTPart 1 – Cigall Kadoch, Ph.D. (30 min.)Exome- and genome-wide sequencing studies in human cancer have...
DATE: June 27, 2017TIME: 8:00am PT, 11:00am ETThe purpose of this study is to identify genetic variants that influence cellular responses, and patterns of M.tb infection and growth in h...
The Instrumentation Group at the BC Cancer Agency’s Genome Sciences Centre (GSC) is unusual in having an engineering group and extensive prototyping facilities embedded in a biomedical...
I’ll talk about Strand NGS Server, our server-client NGS offering. Strand NGS server is geared towards small-to-medium scale clinical labs with high-volume sequencing throughputs and lo...
Much has been said about the promise of Next Generation Sequencing (NGS) to revolutionise diagnosis of rare diseases, and there are many examples of success in this arena. However, the majori...
It was 10 years ago that Illumina first launched the Genome Analyzer II, the world’s first high-throughput sequencing platform. That system could produce one billion bps of sequen...
Many computational approaches exist for predicting the effects of amino acid substitutions from protein sequence. These are often (incorrectly) used for judging disease predisposition from in...
DATE: April 18, 2017TIME: 7:30am PT, 10:30am ETLabs large and small that conduct genomic studies are looking for ways to vastly improve NGS sample prep, especially from challenging FFPE...
DATE: February 7, 2017TIME: 10:00am PT, 1:00pm ETIn this webinar, Jeffrey G. Reid, PhD, Executive Director and Head of Genome Informatics at Regeneron Pharmaceuticals, will sh...
DATE: November 16, 2016
TIME: 8:00am PT, 11:00am ET
Breast cancer is the most commonly diagnosed cancer in women and is the second leading cause of cancer death among wo...
Whole genome and exome sequencing is being widely used to identify disease-causing variants in patients with hereditary and rare diseases. Discovering the true disease-causing variants often...
Tumor heterogeneity has been known for a while but quantifying heterogeneity is still a challenge. NGS is the method of choice in the analysis of tumor heterogeneity, however, there are...
Millions of individuals have been sequenced or genotyped and linked with medical records, providing an exciting opportunity for therapeutic target discovery. My lab has been using a resilienc...
Targeted sequencing assays are increasingly used to identify tumor mutations that guide therapeutic decisions. Interpretation of a cancer variant’s origin and therapeutic impact poses a...
It is estimated that by the end of this year more than 1 million people worldwide will have had their genome sequenced. Genomic sequencing is increasingly being integrated into clinical care,...
The rapid implementation of next generation sequencing is changing how genetics and genomics are applied in a clinical setting. However, the quickly evolving technology can be challenging to...
Human breast tumors have been shown to exhibit extensive inter- and intra-tumor heterogeneity. While recent advances in genomic technologies have allowed us to deconvolute this heterogeneity,...
DNASTAR offers an integrated suite of software for accurate assembly and analysis of sequence data from all major next-generation sequencing platforms supporting key workflows including de no...
It has been estimated that every human being carries ~20 rare “natural human gene knockouts”-DNA variants in protein-coding regions of the genome that partially or completely inac...
Oncologists and pathologists are increasingly utilizing information on genomic alterations in tumors to help guide patient care and treatment. Personalis, Inc., a genomic sequencing and inter...
Cancer remains the second leading cause of death in the United States. Most tumors arise from a myriad of genetic changes that dysregulate cell growth and prompt survival. Ident...
Recent advances in next-generation sequencing (NGS) have helped to accelerate the pace of discovery in the field of genetic disease research and testing. The ability to analyze multiple genes...
Medical genetics is a specialty of medicine that encompasses patients at all ages (prenatal, pediatric, adult), as well as all organ systems. As the genetic causes of more diseases have been ...
Follow
